• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Masimo And Cleveland Clinic Collaborate To Improve Hospital Remote Care), Including TeleCritical Care

    6/27/24 10:12:50 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MASI alert in real time by email

    Masimo (NASDAQ:MASI), a leading global provider of medical technology and hospital automation solutions, and Cleveland Clinic, a nonprofit academic medical center, announced today the launch of a new partnership centered around hospital-based remote patient monitoring (RPM), including TeleCritical Care. This will include the integration of Cleveland Clinic's critical care (eHospital) and non-critical care (eCMU) central patient monitoring platforms with the Masimo Hospital Automation™ platform. The goal is to provide tools for clinicians that offer enhanced situational awareness and clinical decision-support for hospitalized patients, including the critically ill.

    Get the next $MASI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MASI

    DatePrice TargetRatingAnalyst
    12/27/2024$170.00 → $194.00Outperform
    Raymond James
    11/6/2024$170.00Mkt Perform → Outperform
    Raymond James
    6/3/2024$126.00 → $160.00Neutral → Overweight
    Piper Sandler
    4/15/2024$148.00 → $170.00Hold → Buy
    Stifel
    3/25/2024$117.00 → $160.00Equal Weight → Overweight
    Wells Fargo
    1/30/2024$107.00 → $121.00Buy → Hold
    Jefferies
    1/3/2024Buy → Hold
    Needham
    11/8/2023Outperform → Mkt Perform
    Raymond James
    More analyst ratings

    $MASI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New Study Finds Masimo SedLine® Brain Function Monitoring Offers Significant Advantages During Pediatric Anesthesia

      EEG-Guided Anesthesia Using Masimo Technology Significantly Reduced Pediatric Anesthesia Emergence Delirium, Time to Emergence and Discharge, and Cost of Care by Minimizing Sevoflurane Exposure Masimo (NASDAQ:MASI) today announced the findings of a randomized clinical trial published in JAMA Pediatrics in which Dr. Yasuko Nagasaka and colleagues at Tokyo Women's Medical University demonstrated the ability of electroencephalogram (EEG)-guided anesthesia, using Masimo SedLine® Brain Function Monitoring, to improve anesthesia administration in children undergoing surgery.1 The researchers found that the use of SedLine led to a significant reduction in the amount of a commonly used inhalation

      6/10/25 8:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo to Present in the Jefferies Global Healthcare Conference

      Masimo (NASDAQ:MASI) today announced that its management will participate in the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 1:25 p.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ:MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bower

      5/27/25 9:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo to Present in the BofA Securities 2025 Health Care Conference

      Masimo (NASDAQ:MASI) today announced that its management will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 4:20 p.m. Pacific time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ:MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bo

      5/7/25 9:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    SEC Filings

    See more
    • SEC Form SD filed by Masimo Corporation

      SD - MASIMO CORP (0000937556) (Filer)

      5/27/25 5:27:13 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - MASIMO CORP (0000937556) (Filer)

      5/27/25 9:00:17 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 144 filed by Masimo Corporation

      144 - MASIMO CORP (0000937556) (Subject)

      5/12/25 4:39:26 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Muhsin Bilal exercised 10,000 shares at a strike of $34.51 and sold $1,632,781 worth of shares (10,000 units at $163.28) (SEC Form 4)

      4 - MASIMO CORP (0000937556) (Issuer)

      5/14/25 5:32:56 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Solomon Darlene J. S. converted options into 1,790 shares (SEC Form 4)

      4 - MASIMO CORP (0000937556) (Issuer)

      5/2/25 8:55:57 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Scannell Timothy J converted options into 1,383 shares (SEC Form 4)

      4 - MASIMO CORP (0000937556) (Issuer)

      5/2/25 8:54:23 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    Financials

    Live finance-specific insights

    See more
    • Masimo Reports First Quarter 2025 Results

      Masimo Corporation (NASDAQ:MASI) today announced its financial results for the first quarter ended March 29, 2025. First Quarter 2025 Results From Continuing Operations(1): GAAP revenue of $372 million, representing 10% on a reported basis; Non-GAAP revenue of $371 million, representing 10% on a constant currency basis(3); GAAP net income per diluted of $0.86; and Non-GAAP net income per diluted share(3) of $1.36, which grew 56% versus prior year period. First Quarter 2025 Results From Discontinued Operations(2): GAAP loss from discontinued operations, net of tax was ($218) million, which included an impairment of intangibles of $295 million for the non-healthcare consumer busi

      5/6/25 4:10:00 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo to Report First Quarter 2025 Financial Results after Market Close on Tuesday, May 6

      Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release first quarter 2025 financial results for the period ended March 29, 2025, after the market closes on Tuesday, May 6, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call will also be sent to registered participant

      4/24/25 9:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Updated Full-Year 2025 Guidance

      Masimo (NASDAQ:MASI) today announced its financial results for the fourth quarter and full-year ended December 28, 2024 and provided updated estimates for its full-year 2025 guidance. Fourth Quarter 2024 Financial Results: Consolidated revenue was $601 million, representing 9% growth on a reported and constant currency basis(1); Healthcare revenue was $368 million, representing 8% growth on a reported basis and 9% growth on a constant currency basis(1); Non-healthcare revenue was $232 million, representing 11% growth on a reported and constant currency basis(1); GAAP net loss per basic share was ($6.52), which included an impairment of goodwill and intangibles for Sound United

      2/25/25 4:05:00 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James reiterated coverage on Masimo with a new price target

      Raymond James reiterated coverage of Masimo with a rating of Outperform and set a new price target of $194.00 from $170.00 previously

      12/27/24 7:29:29 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo upgraded by Raymond James with a new price target

      Raymond James upgraded Masimo from Mkt Perform to Outperform and set a new price target of $170.00

      11/6/24 7:17:22 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Masimo from Neutral to Overweight and set a new price target of $160.00 from $126.00 previously

      6/3/24 7:31:43 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    Leadership Updates

    Live Leadership Updates

    See more

    $MASI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Dexcom Appoints Jon Coleman as Chief Commercial Officer

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

      3/25/25 4:05:00 PM ET
      $DXCM
      $MASI
      $PFE
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Pharmaceutical Preparations
    • Masimo Announces Leadership Transition

      Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

      1/21/25 4:00:00 PM ET
      $MASI
      $NARI
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

      Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns

      10/18/24 9:00:00 AM ET
      $ENV
      $LH
      $MASI
      $MSCI
      Business Services
      Consumer Discretionary
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Masimo Corporation

      SC 13D/A - MASIMO CORP (0000937556) (Subject)

      9/25/24 4:01:23 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Masimo Corporation

      SC 13D/A - MASIMO CORP (0000937556) (Subject)

      8/30/24 4:56:53 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Masimo Corporation

      SC 13D/A - MASIMO CORP (0000937556) (Subject)

      7/17/24 5:29:36 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care